Since OS has been found to be significantly associated with MPR,12,13 it would be worthwhile to investigate whether the combination of chemotherapy with EGFR-TKI as neoadjuvant treatment can improve the OS in patients with NSCLC with EGFR mutations and stage III-N2 disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.